Cristina Tarango, MD
- Medical Director, Hemophilia Treatment Center
- Professor, UC Department of Pediatrics
- cristina.tarango@cchmc.org
- Board Certified
About
Biography
As a pediatric hematologist, I treat children with conditions such as hemophilia, von Willebrand disease, thrombosis (blood clots) and other blood conditions. I try to treat each patient the way I would want my family members to be cared for. It’s very important for patients and families to take an active role in their care and share in the decision-making.
I was influenced in my career choice by a wonderful pediatrician who cared for me when I was growing up. After I became a pediatrician, I chose the field of hematology because it’s so diverse and interesting. At Cincinnati Children’s, I enjoy working with our dedicated group of physicians as well as our excellent nurse care managers, social workers, child life specialists and other professionals who are so committed to supporting children with blood disorders.
In addition to patient care, I conduct research. My studies are focused on gaining a better understanding of thrombosis and its management in children. I am also involved with studies assessing different treatments for hemophilia, as well as evaluating the immune system in patients with hemophilia, both with and without inhibitors. Inhibitors are antibodies that can prevent treatments from working, which makes it more difficult to stop a bleeding episode.
Outside the hospital, I love spending time with my husband and daughter. I also enjoy traveling, reading and volunteering when I can.
MD: Stanford University School of Medicine, Stanford, CA, 2003
Residency: Yale-New Haven Hospital, New Haven, CT, 2006
Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009
Certifications: Pediatrics, 2006; Pediatric Hematology Oncology, 2011
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Research Areas
Additional Languages
SpanishLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Secondary anticoagulation prophylaxis for children with antiphospholipid syndrome: a systematic review and meta-analysis. Blood advances. 2026; 10(17):5991-5994.
Prevalence of Qualitative Platelet Disorders in Adolescents and Young Adults with Heavy Menstrual Bleeding: A Single Center Experience. Research and Practice in Thrombosis and Haemostasis. 2026; 106970.
PB2275 Evolution of Treatment Patterns in Moderate Hemophilia During Early Childhood: A Longitudinal Within-Patient Analysis. Research and Practice in Thrombosis and Haemostasis. 2026; 10:105015.
PB2240 Pediatric Antiphospholipid Syndrome: A Multicenter Retrospective Cohort Study. Research and Practice in Thrombosis and Haemostasis. 2026; 10:104980.
PB2219 Incidence of Platelet Disorders Among Adolescents and Young Adults with Heavy Menstrual Bleeding. Research and Practice in Thrombosis and Haemostasis. 2026; 10:104959.
PB2212 Outcomes of endovascular interventions versus anticoagulation in adolescents with non-catheter associated iliofemoral deep venous thrombosis (DVT): a preliminary analysis of a multi-institutional cohort study. Research and Practice in Thrombosis and Haemostasis. 2026; 10:104952.
PB2105 Prevention of Bleeding in Patients with Moderate and Severe Hemophilia A Playing Sports: A Comparison between Factor VIII and Emicizumab Prophylaxis - STEP: SporTs Emicizumab Prophylaxis. - Interim Analysis. Research and Practice in Thrombosis and Haemostasis. 2026; 10:104844.
Efficacy and safety of anticoagulation for pediatric cerebral sinovenous thrombosis: systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 2026; 10(6):106905.
Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial. The Lancet Haematology. 2026; 13(7):e471-e483.
ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. Blood advances. 2026; 10(12):4303-4333.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey